Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII; Amunix Could Recieve up to $39M

By: via Benzinga
Amunix Operating Inc. announced today that Biogen Idec (NASDAQ: BIIB) has exercised its option to enter into an exclusive, worldwide ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.